Theracryf Plc

EVG

GB00BSVYN304

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:01 2024-04-26 am EDT			5-day change	1st Jan Change
0.8 ^GBX	0.00%		+3.23%	-50.00%

Apr. 26	Evgen Pharma plc will Change its Ticker to TCF from EVG	CI
Apr. 26	Evgen Pharma plc will Change its Name to TheraCryf plc	CI

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

January 15, 2024

Evgen Pharma plc announced a private placement for the gross proceeds of $17,400,000 on January 16, 2024. The transaction included participation from new investor Stalicla SA.

Latest news about Theracryf Plc

Evgen Pharma plc will Change its Ticker to TCF from EVG	Apr. 26	CI
Evgen Pharma plc will Change its Name to TheraCryf plc	Apr. 26	CI
Norcros sells Johnson Tiles UK; Trifast trading well	Apr. 25	AN
Northcoders launches bootcamp; Schroder invests	Apr. 04	AN
Evgen Pharma Concludes Retail Offer of Shares	Apr. 04	MT
Evgen Pharma Signs Takeover Deal with Chronos Therapeutics; Raises Capital Via Share Issue, Subscription	Mar. 20	MT
EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat	Mar. 19	AN
Evgen Pharma plc agreed to acquire Chronos Therapeutics Ltd. from group of shareholders for £3.4 million.	Mar. 18	CI
Evgen Pharma finds evidence of SFX-01 activity in colon cancer models	Feb. 27	AN
Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer	Feb. 27	CI
Evgen Pharma shares up on studies into SFX-01 product progressing well	Feb. 19	AN
Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells	Feb. 19	CI
Apax opts against lifting offer; DCI enters loan deal	Feb. 09	AN
FTSE 100 falls at end of tepid week	Feb. 09	AN
Evgen Pharma Issues Notice of Dispute to Stalicla Over Missed Milestone Payment	Feb. 09	MT
Evgen partner raises USD17.4 million to support pipeline	Jan. 16	AN
Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA	Jan. 15	CI
Evgen appoints Toni Hanninen as permanent CFO	Dec. 22	AN
Evgen Pharma Interim CFO to Assume Post Permanently	Dec. 22	MT
Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024	Dec. 22	CI
Evgen Pharma plc Announces Changes to its Board	Dec. 22	CI
Acuity RM wins contract; Georgia Capital ups earnings	23-10-31	AN
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Revenue GBP396,000	23-10-31	MT
Earnings Flash (EVG.L) EVGEN PHARMA Reports Fiscal H1 Loss GBX-0.53	23-10-31	MT
Evgen Pharma plc Reports Earnings Results for the Half Year Ended September 30, 2023	23-10-31	CI

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage drug development company. The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. Its core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Theracryf Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERACRYF PLC	-50.00%	4.26M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Theracryf Plc

Equities

EVG

GB00BSVYN304

Biotechnology & Medical Research

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

Latest news about Theracryf Plc

Chart Theracryf Plc

Company Profile

Income Statement Evolution

Ratings for Theracryf Plc

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs